logo

For the Inventor, By the Inventor

Brussels, Belgium

Patrick Chomez

This inventor holds 5 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 1994-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Chomez. Retrieved from https://idiyas.com/inventor/patrick-chomez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 207(Granted Patents)


Company Filing History:

goldMedal5 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents

Years Active: 1994-2011

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7923534 - Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 (2011-04-12),
2. RE40089 - Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor (2008-02-18),
3. 5925729 - Tumor rejection antigen precursors, tumor rejection antigens and uses (1999-07-20),
4. 5612201 - Isolated nucleic acid molecules useful in determining expression of a (1997-03-18),
5. 5342774 - Nucleotide sequence encoding the tumor rejection antigen precursor, (1994-08-30),

Title: The Innovative Contributions of Patrick Chomez

Introduction

Patrick Chomez is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly through his work on tumor rejection antigens. With a total of 5 patents, Chomez has established himself as a key figure in the development of innovative therapeutic solutions.

Latest Patents

Among his latest patents are the isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3. This invention relates to an isolated DNA sequence that codes for an antigen expressed by tumor cells, which is recognized by cytotoxic T cells, leading to the lysis of the tumor that expresses it. Additionally, he has developed nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor, which also involves an isolated DNA sequence with similar therapeutic implications.

Career Highlights

Patrick Chomez is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer immunology. His work has been instrumental in understanding how the immune system can be harnessed to target and destroy cancer cells.

Collaborations

Chomez has collaborated with esteemed colleagues such as Etienne De Plaen and Pierre Van Der Bruggen. These partnerships have further enriched his research and contributed to the advancement of cancer therapies.

Conclusion

Patrick Chomez's innovative work in the field of cancer research exemplifies the impact of dedicated inventors on medical science. His patents and collaborations highlight the importance of continued research in developing effective cancer treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…